Emory ALS Center

Due to the COVID-19 pandemic, follow-up and multidisciplinary clinic visits for current Emory ALS Center patients are available by telemedicine only.  Please call 404-778-3444 or use the patient portal to request an appointment.  New patient referrals can be made to our center by faxing records to 404-778-3495.  

An experimental gene-silencing drug designed for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a clinical trial conducted at the Emory ALS Center and other medical centers around the world.

The trial indicated that the “antisense” drug, known as tofersen, lowers levels of a disease-causing protein in people with a type of ALS caused by mutations in the gene SOD1. The results of the study, published in New England Journal of Medicine, have led to the launch of a phase 3 clinical trial to further evaluate the safety and efficacy of tofersen.

Although the study was primarily meant to evaluate safety and whether the drug lowers levels of the target protein, there are preliminary signs that high doses of tofersen slowed clinical progression of ALS. Read article here...

The Emory ALS Center is part of the Emory Brain Health Center in Atlanta, GA. Led by Dr. Jonathan Glass, it is recognized nationally as a Treatment Center of Excellence by the ALS Association (ALSA) , and is designated a Certified ALS Center by the Muscular Dystrophy Assocation (MDA).  The Emory ALS Center is now one of the largest clinical centers for ALS in the United States. Our team approach to ALS care and research bridges multiple disciplines and departments.  We are physicians, nurses, therapists, social workers, basic and clinical research scientists, students, fellows, and volunteers.  We work together, all with the same goal, but with different expertise and viewpoints.  Our slogan, “Celebrate Life, Imagine a Cure,” is what we do every day.